BRIEF-Antibe Therapeutics appoints new board member

Tue Jul 19, 2016 8:03am EDT
 
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

July 19 (Reuters) - Antibe Therapeutics :

* Anticipates that final results will be available for release by mid-august

* Antibe Therapeutics Announces The Appointment Of New Board Member And Provides Update On Phase 2 Trial Of Atb-346

* Antibe anticipates that final results will be available for release by mid-august

* Elected to pay in-kind all interest due July 15, 2016 under company's 10% senior secured convertible debentures due October 15, 2018

* Aggregate July 15, 2016 interest payment under debentures in amount of $79,521.56 has been added to principal amount of debentures Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)